Biocon, Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Canada

Bengaluru, Apr 28 (PTI) Biocon Ltd. and Mylan N.V.on Tuesday announced the launch of Fulphila, a biosimilar to Neulasta (pegfilgrastim), in Canada.

Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs, Bengaluru- headquartered Biocon said in a statement.

The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data, which confirmed that the product is highly similar to Neulasta and no clinically meaningful differences in terms of safety and efficacy exist, it said.PTI RS SS

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)